Orlistat (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Orlistat" in French language version.

refsWebsite

Global rank French rank

5doi.org

2^nd place

3^rd place

2bmj.com

1,226^th place

347^th place

2nih.gov

4^th place

12^th place

2europa.eu

68^th place

67^th place

1qmul.ac.uk

1,735^th place

168^th place

1rocheusa.com

low place

1lemonde.fr

83^rd place

2^nd place

1pharmacorama.com

low place

5,927^th place

1myalli.com

low place

1wsj.com

79^th place

267^th place

1rxlist.com

7,927^th place

low place

1diabetesjournals.org

low place

7,774^th place

1nature.com

234^th place

147^th place

1nice.org.uk

3,258^th place

low place

1fda.gov

447^th place

1,409^th place

1scielo.br

1,606^th place

2,658^th place

1guardian.co.uk

197^th place

166^th place

1prescriptionaccess.org

low place

1afssaps.fr

low place

3,181^st place

afssaps.fr

Orlistat (Alli, Xenical) : Mise en garde concernant le risque d’hépatotoxicité - Point d'information, communiqué de l'AFSSAPS, 23 septembre 2011

bmj.com

Rucker D, Padwal R, Li SK, Curioni C, Lau DCW, Long term pharmacotherapy for obesity and overweight: updated meta-analysis, BMJ, 2007;335:1194-9.
Douglas IJ, Langham J, Bhaskaran K, Brauer R, Smeeth L, Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink, BMJ, 2013;346:f1936

diabetesjournals.org

care.diabetesjournals.org

(en) J. Torgerson, J. Hauptman, M. Boldrin et L. Sjöström, « XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients », Diabetes Care, vol. 27, n^o 1,‎ 2004, p. 155–61 (PMID 14693982, DOI 10.2337/diacare.27.1.155, lire en ligne)

doi.org

dx.doi.org

(en) J Bodkin, E Humphries et M McLeod, « The total synthesis of (−)-tetrahydrolipstatin », Australian Journal of Chemistry, vol. 56, n^o 8,‎ 2003, p. 795–803 (DOI 10.1071/CH03121)
(en) P. Barbier et F. Schneider, « Syntheses of tetrahydrolipstatin and absolute configuration of tetrahydrolipstatin and lipstatin », Helvetica Chimica Acta, vol. 70, n^o 1,‎ 1987, p. 196–202 (DOI 10.1002/hlca.19870700124)
(en) A. Pommier, M. Pons et P. Kocienski, « The first total synthesis of (–)-lipstatin », Journal of Organic Chemistry, vol. 60, n^o 22,‎ 1995, p. 7334–7339 (DOI 10.1021/jo00127a045)
(en) J. Torgerson, J. Hauptman, M. Boldrin et L. Sjöström, « XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients », Diabetes Care, vol. 27, n^o 1,‎ 2004, p. 155–61 (PMID 14693982, DOI 10.2337/diacare.27.1.155, lire en ligne)
(en) Mancini MC, Halpern A, « Pharmacological treatment of obesity », Arq Bras Endocrinol Metab, vol. 50, n^o 2,‎ 2006, p. 377–89 (PMID 16767304, DOI 10.1590/S0004-27302006000200024) Free full text with registration

europa.eu

ema.europa.eu

European Medicines Agency, European Medicines Agency confirms positive benefit-risk balance of orlistat-containing medicines, 2012

emea.europa.eu

Rapport européen public d'évaluation de l'Alli

fda.gov

(en) Roche Pharmaceuticals, « Xenical Product Label » [PDF, 300 KiB], U.S. Food and Drug Administration, 5 janvier 2007 (consulté le 19 février 2007)

guardian.co.uk

(en) A bitter pill for slimmers?

lemonde.fr

La pilule anti-obésité Alli n'est plus commercialisée depuis 2012, Le Monde, 6 septembre 2013

myalli.com

(en) « myalli.com – frequently asked questions », GlaxoSmithKline, 2007 (consulté le 18 août 2007)

nature.com

Padwal R, Kezouh A, Levine M, Etminan M, Long-term persistence with orlistat and sibutramine in a population-based cohort, Int J Obes (Lond), 2007;31:1567–1570

nice.org.uk

publications.nice.org.uk

National Institute for Health and Care Excellence, Obesity: guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children, 2006

nih.gov

ncbi.nlm.nih.gov

(en) J. Torgerson, J. Hauptman, M. Boldrin et L. Sjöström, « XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients », Diabetes Care, vol. 27, n^o 1,‎ 2004, p. 155–61 (PMID 14693982, DOI 10.2337/diacare.27.1.155, lire en ligne)
(en) Mancini MC, Halpern A, « Pharmacological treatment of obesity », Arq Bras Endocrinol Metab, vol. 50, n^o 2,‎ 2006, p. 377–89 (PMID 16767304, DOI 10.1590/S0004-27302006000200024) Free full text with registration

pharmacorama.com

Hypolipémiants sur pharmacorama.com, consulté le 28 juin 2009

prescriptionaccess.org

(en) PAL Announces First Bitter Pill Award of 2007 to GlaxoSmithKline: "With Allies Like This, Who Needs Enemas?" Award

qmul.ac.uk

chem.qmul.ac.uk

Masse molaire calculée d’après « Atomic weights of the elements 2007 », sur www.chem.qmul.ac.uk.

rocheusa.com

(en) Xenical (orlistat) capsules, product information, consulté le 28 juin 2009

rxlist.com

(en) « Xenical Pharmacology, Pharmacokinetics, Studies, Metabolism », RxList.com, 2007 (consulté le 16 mars 2007)

scielo.br

(en) Mancini MC, Halpern A, « Pharmacological treatment of obesity », Arq Bras Endocrinol Metab, vol. 50, n^o 2,‎ 2006, p. 377–89 (PMID 16767304, DOI 10.1590/S0004-27302006000200024) Free full text with registration

wsj.com

online.wsj.com

(en) Parker-Pope, Tara. "Weighing the Pros and Cons Of New Fat-Blocking Drug Alli", The Wall Street Journal, June 19, 2007, pp. D1.